Nanobiotix amends global licensing agreement for JNJ01900, extends cash visibility to mid-2026
- Co announced the execution of another disciplined step in its financial strategy through the amendment of the Company's global licensing agreement with Janssen Pharmaceutica NV, a Johnson & Johnson (JNJ) company.
- The amendment removes Nanobiotix's funding obligation for NANORAY-312 and releases Johnson & Johnson from select future potential milestone payments, while safeguarding Nanobiotix's path to sustainable cashflow through significant potential milestone payments.